Analysts expect ESSA Pharma Inc. (CVE:EPI) to report $-0.57 EPS on December, 10.They anticipate $1.63 EPS change or 74.09 % from last quarter’s $-2.2 EPS. After having $-0.65 EPS previously, ESSA Pharma Inc.’s analysts see -12.31 % EPS growth. It closed at $4.4 lastly. It is down 0.00% since November 14, 2017 and is . It has underperformed by 15.62% the S&P500.
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on the development of novel therapeutics for the treatment of prostate cancer. The company has market cap of $27.77 million. It is developing EPI-506 that is in Phase 1/2 clinical trials for the treatment of prostate cancer. It currently has negative earnings.